Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.
AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.
AMRI, which has backed away from drug discovery in an ongoing restructuring, opened a collaboration-friendly center for early-stage development through a government partnership.
AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.
Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.
AMRI, the Albany, NY-based company that has been moving away from drug discovery toward manufacturing, said it's teaming with Saneca Pharmaceuticals of Slovakia to produce and sell a suite of opium-derived APIs.
New York-based CMO AMRI has seen its contract manufacturing grow big time after picking up a number of competitors. CEO William Marth says after its latest deal for a Spanish specialty drugmaker, that growth should carry through the year.
AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.
Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.
Albany, NY-based contract manufacturer AMRI has continued its buying spree for more and more diverse manufacturing capacity, and the deals are getting larger. Its latest is a $174 million deal for a drugmaker in Spain that makes specialty APIs and sterile injected drugs.